Co-Chairs: F. Peccatori, IT - C. Saura, ES
Host Chairs: E. Felip, ES - X. Maldonado, ES
Honorary Advisor: N. Pavlidis, GR
Advisor: G. Baciarello, IT
The 20th Western Europe Masterclass in Clinical Oncology is a closed event for selected participants only.
The deadline for applications is 5 June 2022.
Aims, objectives and teaching format
The Masterclass is a full immersion, clinical oriented event designed for medical and clinical oncologists focusing on multidisciplinarity. The programme will expose participants to a full spectrum of issues in clinical oncology and to practice-oriented training.
It offers plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines. Participants will deliver case presentations within tumour boards and discuss them with an international faculty of top experts of each tumour type.
The Masterclass will be entirely in English and fluency in English is necessary for admission.
IDEAL PROFILE OF THE MASTERCLASS CANDIDATE
• Age between 30 and 40 years
• At least 2-3 years’ experience in medical oncology or clinical oncology
• Involvement in scientific activities
• Fluency in English
The Online Masterclass will be carried out in two different parts:
Pre-recorded sessions will be made available via this website. You will be able to see all the sessions in your own time.
The pre-recorded sessions must be viewed before block 2 (Live event).
When you finish watching a set of sessions on a specific tumour, please send us up to 3 questions related to the sessions. Some of your questions will be selected and answered during part 2 in the Q&A sessions.
The in person event will be held from 23 to 27 September 2022.
During the live event, a lecture will be delivered for each main tumour group and will cover topics of interest for oncologists working in the Western European area. Each lecture will be followed by a Q&A session using some of the questions that were sent for block 1.
All participants will present a clinical case and discuss it with the experts.
It is possible we may need to change the participants' case topic in order to keep a balance between all tumour types.
Philippe Aftimos, Institut Jules Bordet, Dept. of Medical Oncology, Anderlecht, BE
Anne Arber, University of Surrey, Faculty of Health and Medical Sciences, Guildford, UK
Giulia Baciarello, National Cancer Institute - IRCCS Foundation, Genitourinary Oncology Dpt., Milano, IT
Joerg Beyer, University Hospital of Bern, Oncology and Medicine Dept., Bern, CH
Jean-Yves Blay, University Claude Bernard Lyon I, Centre Léon Bérard, Dept. of Medicine, Lyon, FR
Silvia Cabrera, Vall d’Hebron Barcelona Hospital Campus, Gynaecological Oncology Unit, Barcelona, ES
Felipe A. Calvo Manuel, Clinica Universidad de Navarra, Dept. of Radiation Oncology, Madrid, ES
Fatima Cardoso, Champalimaud Clinical Center, Breast Unit, Lisbon, PT
Maria-João Cardoso, Champalimaud Foundation, Breast Unit, Lisbon, PT
Ilaria Colombo, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
Giuseppe Curigliano, European Institute of Oncology / University of Milan, New Drugs for Innovative Therapies Division, Milano, IT
Alessandra Curioni-Fontecedro, University Hospital Zurich, Dept. fo Oncology, Zurich CH
Evandro de Azambuja, Jules Bordet Institute, Breast Data Center, Brussels, BE
Sara De Dosso, Oncology Institute of Southern Switzerland (IOSI), Medical Oncology Dpt., Bellinzona, CH
Johan De Munter, University Hospital Ghent, Cancer Centre, Ghent, BE
Rodrigo Dienstmann, Vall d’Hebron Institute of Oncology, Molecular Therapeutic Research Unit, Barcelona, ES
Andreas Dietz, University Hospital Leipzig, ENT Dpt., Leipzig, DE
Elena Élez, Regarding the risk assessment in stage II colon: All of the following are risk parameters but only one is considered a Major prognostic parameter. Please choose the major prognostic parameter:
Alexandru Eniu, Riviera-Chablais Hospital, Interdisciplinary Oncology Service, Rennaz, CH
Eloy Espin Basany, Vall d’Hebron. Barcelona Hospital Campus, General Surgery Dpt., Barcelona, ES
Martin Espinosa-Bravo, Vall d’Hebron Barcelona Hospital Campus, Gynaecology Service, Barcelona, ES
Enriqueta Felip, Vall d'Hebron University Hospital, Dept. of Oncology, Barcelona, ES
Karim Fizazi, Gustave Roussy Institute, Cancer Medicine Dept., Villejuif, FR
Martin Früh, St. Gallen Cantonal Hospital, Dept. of Internal Medicine, St. Gallen, CH
Katarzyna Furrer, University Hospital Zurich, Dept. of Thoracic Surgery, Zurich, CH
Marina Garassino, National Cancer Institute - IRCCS Foundation, Medical Oncology Dept., Milano, IT
Angel García Jiménez, Vall d’Hebron Barcelona Hospital Campus, Dept. of Pathology, Barcelona, ES
Fady B. Geara, Cleveland Clinic Abu Dhabi, Dept. of Radiation Oncology, Abu Dhabi, AE
Alexandra Giraldo Marin, Vall d’Hebron University Hospital, Radiation Oncology Dpt., Barcelona, ES
Robert Glynne-Jones, Mount Vernon Centre for Cancer Treatment, Radiotherapy Department, London, UK
Antonio González Martín, Please select the incorrect statement regarding the evidence of the use of PARP inhibitors as maintenance in front-line
Federica Grosso, Azienda Ospedaliera Nazionale SS. Antonio e Biagio e C. Arrigo, ., Alessandria, IT
Andrew Hoy, Independent Palliative Medicine Practice, Epsom, UK
Izidor Kern, University Clinic Golnik, Dept. of Pathology, Golnik, SI
Stephanie Kroeze, University Hospital Zurich, Radio-Oncology Dept., Zurich, CH
Angela Lamarca, The Christie NHS Foundation Trust, Medical Oncology Dept, Manchester, UK
Xavier Maldonado, Vall d'Hebron University Hospital, Radiation Oncology Dept., Barcelona, ES
Salvador E. Martin Algarra, Clinica Universidad de Navarra, Medical Oncology Dept., Pamplona, Navarra, ES
Gilberto Morgan, What is the most important factor in medical social media
Nicolas Mottet, University Jean Monnet, Dept. of Urology, Saint Etienne Cedex 2, FR
Eva Muñoz Couselo, Vall d'Hebron Hospital, Dept. of Medical Oncology - Melanoma and other skin cancers Unit, Barcelona, ES
Dina Najjari Jamal, Catalan Institute of Oncology, Bellvitge Institute of Biomedical Research, Hospitalet de Llobregat, Barcelona, ES
Christoph Oing, Newcastle upon Tyne Hospitals NHS Foundation Trust, Northern Centre for Cancer Care - Cancer Services Department, Newcastle Upon Tyne, UK
Olivia Pagani, Riviera-Chablais Hospital, Interdisciplinary Oncology Service, Rennaz, CH
Nicholas Pavlidis, University of Ioannina (Emeritus Professor), Oncology Dpt., Ioannina, GR
Fedro Alessandro Peccatori, European Institute of Oncology, Dept. of Fertility and Procreation in Oncology, Milano, IT
Jacques Planas Morin, Vall d’Hebron Barcelona Hospital Campus, Oncology Service, Barcelona, ES
Graeme John Poston, Aintree University Hospital, Dept. of Surgery, Liverpool, UK
Giancarlo Pruneri, National Cancer Institute, IRCCS Foundation, Pathology Dpt., Milano, IT
Amanda Psyrri, Attikon University Hospital, Medical Oncology Dept., Chaidari, GR
Isabelle Ray-Coquard, Léon Bérard Center, Dept. of Medical Oncology, Lyon, FR
Victoria Reyes, Vall d’Hebron Institute of Oncology, Radiotherapy Group, Barcelona, ES
Christian Rolfo, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Center for Thoracic Oncology, New York, US
Laura Rubbia-Brandt, Hôpitaux Universitaires Genève, Pathology Dept., Geneve, CH
Irene Sansano, Vall d'Hebron University Hospital, Institute of Pathology, Barcelona, ES
Cristina Saura, Vall d'Hebron University Hospital, Barcelona, ES
Fernando Schmitt, Unit of Molecular Pathology, Institute of Molecular Pathology - IPATIMUP, Porto, PT
Cristiana Sessa, Istituto Oncologico della Svizzera Italiana, Gynaecology Dpt., Bellinzona, CH
Thomas Seufferlein, Ulm University Hospital, Dept. of Internal Medicine I, Ulm, DE
Elizabeth Smyth, The following predictive biomarkers are recommended to be checked in advanced gastroesophageal adencoarcinoma
Arndt Vogel, Medizine Hochschule Hannover, Gastrointestinal Oncology Dpt., Hannover, DE
Ursula Vogl, Cantonal Hospital of Southern Switzerland (EOC), IOSI - Oncology Institute of Southern Switzerland, Bellinzona, CH
Ignacio Zapardiel, La Paz University Hospital, Gynecologic Oncology Unit, Madrid, ES
The Masterclass will be held in English and translation will not be provided.
Participants will be issued a certificate of attendance (minimum attendance: 75% of the online part + 100% of the in person event). An online evaluation questionnaire and learning assessment test will need to be completed in order to get the certificate that will be issued by email.
Application for CME recognition will be submitted to the Accreditation Council of Oncology in Europe (ACOE). The American Medical Association (AMA) and the Accreditation Council for Continuous Medical Education (ACCME) designate this type of educational activity for a maximum of 1 AMA PRA category 1 credits per hour of activity.
ESCO - The ESO College
Being selected to take part in an ESO Masterclass is one of the ESO activities that gives participants eligibility to enrol in ESCO - the College of the European School of Oncology.
A Masterclass also enables ESCO students to earn ESCO credits and therefore access more ESCO benefits.
Full and active participation in the Masterclass earns participants 30 ESCO credits.
Visit www.ESCO.org for more information on how to join ESCO.
Use the hashtag #ESOexperience and follow us on Facebook, Twitter and Instagram: @esoncology
Should you have any queries, please do not hesitate to contact the event organisers:
Francesca Marangoni - firstname.lastname@example.org
Corinne Hall - email@example.com
Mariachiara Deleo - firstname.lastname@example.org
ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY
PARTICIPANT’S PROFILE OF THE MASTERCLASS CANDIDATE
- Age between 30 and 40 years
- 2-3 years’ experience in medical oncology
- Involvement in scientific activities and clinical trials
- Fluency in English
HOW TO APPLY
Interested oncologists should apply online (at the top of this page) providing:
- Letter describing motivation for attending;
- Supporting letter from head of department or mentor;
- CV with list publications (if the list of publications is not provided, it will be assumed that no articles have been published)
- Clinical case (see below)
- Professional experience form (see below)
Priority will be given to candidates practicing in the Western European countries.
CLINICAL CASE PRESENTATION
You will have to present a clinical case at the Masterclass as a clinical grand round discussion. Please provide a straightforward case of your daily clinical practice - no uncommon or extremely rare cases. A maximum of 10 slides will be permitted containing:
- Diagnostic considerations
- Results, follow-up
- At least three questions proposed for discussion with the faculty
Before you start completing the online application form, please be sure you have all the requested files (CV, Motivation letter, Supporting letter, Professional experience template and Clinical Case template) ready to be uploaded to the system. Online applications will not be complete unless all the files are uploaded.